Should Any One Airway Clearance Technique be Recommended for People With Cystic Fibrosis? (ACT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00890370 |
Recruitment Status :
Completed
First Posted : April 29, 2009
Last Update Posted : April 29, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cystic Fibrosis | Procedure: Airway clearance technique | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 75 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Comparison of Five Airway Clearance Techniques in the Treatment of Adults With Cystic Fibrosis |
Study Start Date : | July 1999 |
Actual Primary Completion Date : | September 2003 |
Actual Study Completion Date : | September 2003 |

Arm | Intervention/treatment |
---|---|
1
Active cycle of breathing techniques
|
Procedure: Airway clearance technique |
2
Autogenic drainage
|
Procedure: Airway clearance technique |
3
R-C Cornet
|
Procedure: Airway clearance technique |
4
Flutter
|
Procedure: Airway clearance technique |
5
PEP
|
Procedure: Airway clearance technique |
- Forced expiratory volume in one second (FEV1) [ Time Frame: 48 weeks ]
- Quality of life (Short Form-36 and Chronic Respiratory Questionnaire) [ Time Frame: 48 weeks ]
- Exercise capacity (Modified shuttle test) [ Time Frame: 48 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of cystic fibrosis (genotype or sweat sodium concentration greater than 70 mmol/litre)
- Forced expiratory volume in one second greater than or equal to 25% predicted, on assessment for entry to the study.
Exclusion Criteria:
- Evidence of a current respiratory exacerbation (Thornton et al 2004)
- Current severe haemoptysis
- Past history of pneumothorax
- Awaiting lung / heart-lung transplantation
- Pregnancy
- Recent (within 3 months) acquisition of Burkholderia cepacia

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00890370
Principal Investigator: | Jennifer A Pryor, PhD | Royal Brompton & Harefield NHS Foundation Trust |
Responsible Party: | Dr Jennifer A Pryor, Royal Brompton & Harefield NHS Trust |
ClinicalTrials.gov Identifier: | NCT00890370 |
Other Study ID Numbers: |
1998CF004B |
First Posted: | April 29, 2009 Key Record Dates |
Last Update Posted: | April 29, 2009 |
Last Verified: | April 2009 |
Cystic fibrosis Airway clearance |
Cystic Fibrosis Fibrosis Pathologic Processes Pancreatic Diseases Digestive System Diseases |
Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases |